Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Flerie ABFRA:1NP1 -1.71%37 Receivables Turnover is 1.43 as of Jun. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 842 Biotechnology companies, Flerie AB ranks worse than 80.52% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Flerie AB's Revenue for the
three
months ended in Jun. 2026 was €0.12 Mil. Flerie AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was €0.08 Mil.
Hence, Flerie AB's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.43.
Flerie AB (FRA:1NP1) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Flerie AB Receivables Turnover Related Terms
Flerie AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Flerie AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1NP1 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Flerie AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Flerie AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a Receivables Turnover of 1.43 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #678 out of 842 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Flerie AB's Receivables Turnover too high?
Flerie AB's current Receivables Turnover is 1.43. The Biotechnology industry median Receivables Turnover is 5.30. Flerie AB's value of 1.43 is 73% below this industry median. Based on the distribution chart, Flerie AB ranks #678 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Flerie AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #678 out of 842 companies for Receivables Turnover. This places Flerie AB in the lower half of its industry. The industry median Receivables Turnover is 5.30. Flerie AB's value of 1.43 is 73% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Flerie AB's current Receivables Turnover of 1.43 is 73% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current Receivables Turnover is 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current Receivables Turnover of 1.43. The current Receivables Turnover is 1.43 and 73% below the Biotechnology industry median of 5.30. Flerie AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current Receivables Turnover is 1.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
37GF Score
Get the complete analysis for FRA:1NP1
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
